Subrata Debnath1, Chakradhar Velagapudi1, Laney Redus2, Farook Thameem1, Balakuntalam Kasinath1, Claudia E Hura1, Carlos Lorenzo3, Hanna E Abboud1, Jason C O'Connor2,4. 1. Division of Nephrology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 2. Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 3. Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 4. South Texas Veterans Health Care System, San Antonio, TX, USA.
Abstract
OBJECTIVE: Type 2 diabetes (T2D) is the primary case of chronic kidney disease (CKD). Inflammation is associated with metabolic dysregulation in patients with T2D and CKD. Tryptophan (TRP) metabolism may have relevance to the CKD outcomes and associated symptoms. We investigated the relationships of TRP metabolism with inflammatory markers in patients with T2D and CKD. METHODS: Data were collected from a well-characterized cohort of type 2 diabetic individuals with all stages of CKD, including patients on hemodialysis. Key TRP metabolites (kynurenine [KYN], kynurenic acid [KYNA], and quinolinic acid [QA]), proinflammatory cytokines (tumor necrosis factor-α [TNF-α] and interleukin-6 [IL-6]), and C-reactive protein were measured in plasma. The KYN/TRP ratio was utilized as a surrogate marker for indoleamine 2,3-dioxygenase 1 (IDO1) enzyme activity. RESULTS: There was a significant inverse association between circulating TRP level and stages of CKD (P< 0.0001). Downstream bioactive TRP metabolites KYN, KYNA, and QA were positively and robustly correlated with the severity of kidney disease (P < 0.0001). In multiple linear regression, neither TNF-α nor IL-6 was independently related to KYN/TRP ratio after adjusting for estimated glomerular filtration rate (eGFR). Only TNF-α was independently related to KYN after taking into account the effect of eGFR. CONCLUSIONS: Chronic kidney disease secondary to T2D may be associated with accumulation of toxic TRP metabolites due to both inflammation and impaired kidney function. Future longitudinal studies to determine whether the accumulation of KYN directly contributes to CKD progression and associated symptoms in patients with T2D are warranted.
OBJECTIVE:Type 2 diabetes (T2D) is the primary case of chronic kidney disease (CKD). Inflammation is associated with metabolic dysregulation in patients with T2D and CKD. Tryptophan (TRP) metabolism may have relevance to the CKD outcomes and associated symptoms. We investigated the relationships of TRP metabolism with inflammatory markers in patients with T2D and CKD. METHODS: Data were collected from a well-characterized cohort of type 2 diabetic individuals with all stages of CKD, including patients on hemodialysis. Key TRP metabolites (kynurenine [KYN], kynurenic acid [KYNA], and quinolinic acid [QA]), proinflammatory cytokines (tumor necrosis factor-α [TNF-α] and interleukin-6 [IL-6]), and C-reactive protein were measured in plasma. The KYN/TRP ratio was utilized as a surrogate marker for indoleamine 2,3-dioxygenase 1 (IDO1) enzyme activity. RESULTS: There was a significant inverse association between circulating TRP level and stages of CKD (P< 0.0001). Downstream bioactive TRP metabolites KYN, KYNA, and QA were positively and robustly correlated with the severity of kidney disease (P < 0.0001). In multiple linear regression, neither TNF-α nor IL-6 was independently related to KYN/TRP ratio after adjusting for estimated glomerular filtration rate (eGFR). Only TNF-α was independently related to KYN after taking into account the effect of eGFR. CONCLUSIONS:Chronic kidney disease secondary to T2D may be associated with accumulation of toxic TRP metabolites due to both inflammation and impaired kidney function. Future longitudinal studies to determine whether the accumulation of KYN directly contributes to CKD progression and associated symptoms in patients with T2D are warranted.
Authors: Stefan Löb; Alfred Königsrainer; Derek Zieker; Björn L D M Brücher; Hans-Georg Rammensee; Gerhard Opelz; Peter Terness Journal: Cancer Immunol Immunother Date: 2008-04-17 Impact factor: 6.968
Authors: Jörg C Schefold; Jan-Philip Zeden; Christina Fotopoulou; Stephan von Haehling; Rene Pschowski; Dietrich Hasper; Hans-Dieter Volk; Christine Schuett; Petra Reinke Journal: Nephrol Dial Transplant Date: 2009-01-20 Impact factor: 5.992
Authors: Dawn M Richard; Michael A Dawes; Charles W Mathias; Ashley Acheson; Nathalie Hill-Kapturczak; Donald M Dougherty Journal: Int J Tryptophan Res Date: 2009-03-23
Authors: Katharina Hopp; Emily K Kleczko; Berenice Y Gitomer; Michel Chonchol; Jost Klawitter; Uwe Christians; Jelena Klawitter Journal: Am J Physiol Renal Physiol Date: 2022-01-17
Authors: Mark B Lockwood; Jennifer L Steel; Ardith Z Doorenbos; Blanca N Contreras; Michael J Fischer Journal: Semin Nephrol Date: 2021-11 Impact factor: 5.299
Authors: Vetalise C Konje; Thekkelnaycke M Rajendiran; Keith Bellovich; Crystal A Gadegbeku; Debbie S Gipson; Farsad Afshinnia; Anna V Mathew Journal: Clin Kidney J Date: 2020-04-12